Biotech News
Related news
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-10-02 20:01 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPTSarepta Therapeutics2026-07-27 12:30 EST
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
CRSPCRISPR Therapeutics2026-10-19 20:05 EST
CRISPR Therapeutics Announces Chief Financial Officer Transition
MXCTMaxCyte2026-09-23 12:05 EST
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
EDITEditas Medicine2026-09-08 11:00 EST
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
SRPTSarepta Therapeutics2026-10-22 12:30 EST
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
CRSPCRISPR Therapeutics2026-10-08 12:30 EST
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
ABEOAbeona Therapeutics2026-10-02 11:30 EST
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ABEOAbeona Therapeutics2026-09-16 11:30 EST
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
Intellia
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...
Recent company news
NTLAIntellia2026-10-13 11:30 EST
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
NTLAIntellia2026-10-02 20:01 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-10-02 20:01 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Stock data
- Close
- 11.65 USD
- Market cap
- 1.83B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States